Omnicell (NASDAQ:OMCL) Stock Price Down 13.2%
Omnicell, Inc. (NASDAQ:OMCL) shares were down 13.2% during mid-day trading on Thursday . The stock traded as low as $72.27 and last traded at $75.11, approximately 3,097,710 shares changed hands during mid-day trading. An increase of 798% from the average daily volume of 345,060 shares. The stock had previously closed at $86.52.
A number of analysts have recently weighed in on OMCL shares. Zacks Investment Research upgraded Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Monday, April 29th. Benchmark reissued a “hold” rating on shares of Western Digital in a report on Friday, April 26th. TheStreet cut Trinity Industries from a “b” rating to a “c” rating in a report on Thursday, April 25th. BidaskClub cut Amyris from a “hold” rating to a “sell” rating in a report on Thursday, June 27th. Finally, Craig Hallum upgraded PROS from a “hold” rating to a “buy” rating and upped their price target for the company from $36.00 to $60.00 in a research report on Friday, April 26th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $79.89.
The business’s 50-day moving average price is $83.65. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.47 and a current ratio of 1.96. The stock has a market cap of $3.10 billion, a price-to-earnings ratio of 49.09, a PEG ratio of 2.80 and a beta of 1.13.
In other Omnicell news, Director Joanne B. Bauer sold 3,798 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $81.72, for a total transaction of $310,372.56. Following the completion of the sale, the director now directly owns 20,314 shares in the company, valued at approximately $1,660,060.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Chairman Randall A. Lipps sold 65,161 shares of the business’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $63.77, for a total transaction of $4,155,316.97. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 146,028 shares of company stock worth $10,741,639. Insiders own 2.77% of the company’s stock.
A number of institutional investors have recently modified their holdings of OMCL. Parallel Advisors LLC bought a new position in shares of Omnicell in the 1st quarter valued at about $28,000. Bronfman E.L. Rothschild L.P. increased its holdings in Omnicell by 451.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after buying an additional 506 shares during the period. Nisa Investment Advisors LLC increased its holdings in Omnicell by 125.0% during the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after buying an additional 300 shares during the period. Manchester Capital Management LLC purchased a new position in Omnicell during the first quarter valued at approximately $49,000. Finally, Financial Gravity Wealth Inc. acquired a new stake in Omnicell in the first quarter valued at approximately $50,000. 97.30% of the stock is owned by institutional investors.
Omnicell Company Profile (NASDAQ:OMCL)
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Conference Calls and Individual Investors
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.